Kirov, Ivan I. – M.D.

• Oncology

Ivan Kirov, M.D., is a board certified pediatric hematologist/oncologist. He is CHOC Children’s director of palliative care and director of the lymphoma and recurrent cancer programs in CHOC’s Cancer Institute. Dr. Kirov earned his medical degree from the Medical Academy in Sofia, Bulgary in 1979. He did his residency and fellowship in Bulgaria where he went on to become an accomplished pediatric hematologist/oncologist for more than 20 years.

In 1992, Dr. Kirov moved to the United States and became a visiting fellow in the bone marrow transplant program at the Johns Hopkins Hospital Oncology Center. He then went on to complete a residency in pediatrics at Westchester County Medical Center and postdoctoral fellowship in pediatric hematology/oncology at CHOC. Dr. Kirov has been published in a number of journals including Bone Marrow Transplant and the Journal of Pediatric Hematology/Oncology

Dr. Kirov’s clinical interests include Hodgkin’s and non-Hodgkin’s lymphomas, recurrent cancers, and bone marrow transplants. He is engaged in a number of clinical research projects and is a co-investigator in all ongoing stage one oncology studies at CHOC. He is currently investigating effectiveness of the experimental drug Beudawustim in recurrent leukemia patients. He is also studying defibrotide in the treatment of veno-occlusive disease of the liver after bone marrow transplants.

Dr. Kirov is currently the recipient of two grants from the UCI Chao Family Comprehensive Cancer Center seed funding. One of his funded projects looks at whether loss of SXR expression or function is associated with B-cell lymphomas. The other study is a pilot project to investigate FGFR3 expression and mutations in pediatric patients.

Dr. Kirov was voted as one of Orange County’s Top Doctors in 2009 & 2010.

Published Works

Abla O, Sandlund JT, Sung L, Brock P, Corbett R, Kirov I, Griffin TC, Blaser S, Weitzman S. A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation. Pediatr Blood Cancer. 2006 Dec;47(7):880-5.

Neudorf S, Nourani A, Kempert P, Shen V, Sender L, Kirov I. Chemotherapy and donor leukocyte infusion for relapsed juvenile myelomonocytic leukemia (JMML). Bone Marrow Transplant, 2004; 33: 1069

Kirov I., Shen V., Lones MA.., Primary Central Nervous System B-Cell Lymphoma in Childhood. J Pediatr Hematol Oncol, April 2003; 25 (4): 29.

Kirov I., Neudorf S., Shen V., Lones MA., Peripheral T-Cell Lymphoma (Non-Anaplastic) in Childhood. J Pediatr Hematol Oncol, April 2003; 25 (4): 29.

Lones MA. , Kirov I., Cell Surface Targets For Monoclonal Antibody Therapy in Lymphoid Neoplasms of Children and Adolescents. J Pediatr Hematol Oncol, April 2003; 25 (4): 80 – 82.

Lones MA., Kirov I., Said JM., Shinataku IP., Neudorf S. Post-transplant lympho-proliferative disorder after autologous stem cell transplantation in a pediatric patient. Bone Marrow Transplant 2000; Nov; 26 (9): 1021-1024.

Kirov I., and Neudorf S., Biology and clinical utility of hematopoietic stem cells. Pediatric Pathology and Molecular Medicine 2000; 19: 283-302.

Abu-Ghosh, Bracho F., Kirov I., and Cario MS., Hematopoietic Colony-Stimulating Factors In: Textbook of Critical Care, 4th Edition, Grenik, A (Ed), Philadelphia, Saunders, 2000; pp 542-561.

Konstantinov D., Bobev D., Michailov G., ………Kirov I. A seven years experience in treatment of childhood leukemia in Bulgaria. Pediatric Hematology Oncol 1998 Mar-April; 15(2): 157-164.

Kirov I., Slone V., at all. Generation of Dendritic Cells From Fresh and Cryopreserved, G-CSF Mobilized Peripheral Blood Mononuclear Cells of Patients with Breast Cancer. Proc. Am. Assoc. Cancer Res., 1999; 40: 573.

Presentations
Goldman S. , Kirov I., et al. IL-11 + G-CSF After High Dose Ifosfamide, Carboplatin and Etoposide Mobilizes Large Numbers of CD34+ and CD34+/41+ Progenitor Cells into Peripheral Blood Sufficient for Rapid Hematopoietic Reconstitution Post Myeloablative Therapy in Heavily Pretreated Pediatric Solid tumor Patients: ISEH’98, August 1998, Vancouver, Canada.

Cairo M., Kirov I., et al. Recombinant Human Interleukin 11 Enhances Hematologic Recovery Following ICE Chemotherapy in Children with Solid Tumors and Lymphoma: Analysis of Hematopoietic Responses, Cytokine Induction, Pharmacokinetics and Stem Cell Mobilization: ASCO, 34th Annual Meeting, May 1998, Los Angeles, California.

Goldman S., Kirov I., et al. IL – 11 + G-CSF is an Excellent Cytokine Combination for Peripheral Blood Progenitor Cell Mobilization in Children Following ICE Chemotherapy: ASBMT, Annual Meeting, March 1997, Miami, Florida.

Kirov et al. Recombinant Human Interleukin 11 (Neumega®) is Tolerated at Double the Adult Dose and Enhances Hematopoietic Recovery Following ICE Chemotherapy in Children: Correlation with Rapid Clearance, Lack of Induction of Inflammatory Cytokines and Mobilization of Early Progenitor Cells: ASH, 39th Annual Meeting, December 1997, San Diego, California.